| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| AstraZeneca | | | | | 6.9 | 22.3 | | |
| All other, including affiliated entities | | | | | 0.6 | 3.9 | | |
| Other | | | | | 23.0 | 16.1 | | |
| Total revenues [+] | 10.3 | 1.8 | 7.4 | 4.1 | 30.5 | 42.2 | 35.4 | 40.6 |
| Grants | | | | | | | | 12.9 |
| Revenue growth [+] | 478.2% | -76.1% | 80.2% | -86.5% | -27.8% | 19.4% | -12.8% | 288.0% |
| AstraZeneca | | | | | -69.2% | | | |
| All other, including affiliated entities | | | | | -83.6% | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 10.3 | 1.8 | 7.4 | 4.1 | 30.5 | 42.2 | 35.4 | 40.6 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative [+] | 90.2 | 53.8 | 37.2 | 27.2 | 29.3 | 28.3 | 23.9 | 18.1 |
| General and administrative | 90.2 | 53.8 | 37.2 | 27.2 | 29.3 | 28.3 | 23.9 | 18.1 |
| Research and development | 187.7 | 249.2 | 94.2 | 88.0 | 95.3 | 98.6 | 88.7 | 57.8 |
| Equity in earnings | -2.2 | -0.4 | -4.6 | | | | | |
| Other operating expenses | | | -4.1 | | | | 0.1 | 0.7 |
| EBITDA [+] | -265.6 | -298.1 | -121.0 | -106.4 | -89.1 | -81.2 | -74.3 | -34.1 |
| EBITDA growth | -10.9% | 146.4% | 13.6% | 19.5% | 9.8% | 9.3% | 117.9% | -11.3% |
| EBITDA margin | -2588.0% | -16796.2% | -1632.1% | -2588.7% | -292.3% | -192.3% | -210.0% | -84.0% |
| Depreciation | 3.7 | 3.0 | 3.0 | 3.6 | 3.7 | 1.9 | 1.7 | 1.0 |
| EBITA | -269.2 | -301.1 | -124.0 | -110.0 | -92.8 | -83.0 | -76.0 | -35.1 |
| EBITA margin | -2623.6% | -16967.5% | -1673.1% | -2676.2% | -304.6% | -196.6% | -214.9% | -86.6% |
| Amortization of intangibles | 0.5 | 0.5 | 0.5 | 1.1 | 1.2 | 1.6 | 1.4 | 0.9 |
| EBIT [+] | -269.7 | -301.7 | -124.5 | -111.1 | -94.1 | -84.6 | -77.4 | -36.0 |
| EBIT growth | -10.6% | 142.2% | 12.1% | 18.1% | 11.2% | 9.4% | 114.9% | -10.0% |
| EBIT margin | -2628.5% | -16996.8% | -1680.5% | -2702.1% | -308.7% | -200.5% | -218.8% | -88.7% |
| Non-recurring items [+] | | | 4.1 | | | -1.0 | -1.1 | -1.7 |
| Loss (gain) on sale of assets | | | | | | -1.0 | -1.0 | -1.0 |
| Unusual expense | | | 4.1 | | | | | |
| Interest expense, net [+] | -3.5 | -1.4 | 5.4 | 5.3 | -2.3 | -1.8 | -1.3 | -0.3 |
| Interest expense | 1.3 | 1.9 | 8.7 | 7.9 | | 0.0 | | |
| Interest income | 4.8 | 3.4 | 3.3 | 2.6 | 2.3 | 1.8 | 1.3 | 0.3 |
| Other income (expense), net [+] | -11.4 | -3.0 | -28.8 | -4.4 | -3.0 | -6.4 | 1.2 | 2.8 |
| Change in fair value of warrants | | | | | 0.4 | 0.8 | 0.1 | 0.2 |
| Other | -3.9 | 0.3 | -0.7 | 0.5 | -1.3 | -0.2 | | |
| Pre-tax income | -277.7 | -303.2 | -162.9 | -120.8 | -94.8 | -88.2 | -73.7 | -31.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | -0.3 | 2.2 | 0.0 | 0.0 | -2.1 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.2% | | 0.0% | 0.0% | 6.7% |
| Minority interest | | | -1.1 | -1.2 | | | | 0.1 |
| Net income | -279.8 | -303.7 | -166.4 | -119.4 | -97.0 | -88.2 | -73.7 | -29.2 |
| Net margin | -2726.7% | -17109.9% | -2245.4% | -2902.8% | -318.1% | -208.9% | -208.5% | -71.9% |
| |
| Basic EPS [+] | ($1.17) | ($1.45) | ($1.07) | ($1.21) | ($1.05) | ($1.08) | ($1.01) | ($0.43) |
| Growth | -19.4% | 35.5% | -11.3% | 15.4% | -2.9% | 7.1% | 135.3% | -29.9% |
| Diluted EPS [+] | ($1.17) | ($1.45) | ($1.07) | ($1.21) | ($1.05) | ($1.08) | ($1.01) | ($0.43) |
| Growth | -19.4% | 35.5% | -11.3% | 15.4% | -2.7% | 6.9% | 135.9% | -29.8% |
| |
| Shares outstanding (basic) [+] | 238.6 | 208.8 | 155.1 | 98.7 | 92.5 | 81.8 | 73.2 | 68.2 |
| Growth | 14.3% | 34.6% | 57.1% | 6.7% | 13.2% | 11.7% | 7.4% | 15.3% |
| Shares outstanding (diluted) [+] | 238.6 | 208.8 | 155.1 | 98.7 | 92.5 | 81.9 | 73.2 | 68.4 |
| Growth | 14.3% | 34.6% | 57.1% | 6.7% | 13.0% | 11.9% | 7.1% | 15.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |